Last reviewed · How we verify
TPO-RAs combining anti-CD 20 monoclonal antibody
TPO-RAs combining anti-CD 20 monoclonal antibody is a Small molecule drug developed by Institute of Hematology & Blood Diseases Hospital, China. It is currently FDA-approved. Also known as: TPO-R agonist & anti-CD 20 monoclonal antibody.
At a glance
| Generic name | TPO-RAs combining anti-CD 20 monoclonal antibody |
|---|---|
| Also known as | TPO-R agonist & anti-CD 20 monoclonal antibody |
| Sponsor | Institute of Hematology & Blood Diseases Hospital, China |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- TPO-RAs combining anti-CD 20 monoclonal antibody CI brief — competitive landscape report
- TPO-RAs combining anti-CD 20 monoclonal antibody updates RSS · CI watch RSS
- Institute of Hematology & Blood Diseases Hospital, China portfolio CI
Frequently asked questions about TPO-RAs combining anti-CD 20 monoclonal antibody
What is TPO-RAs combining anti-CD 20 monoclonal antibody?
TPO-RAs combining anti-CD 20 monoclonal antibody is a Small molecule drug developed by Institute of Hematology & Blood Diseases Hospital, China.
Who makes TPO-RAs combining anti-CD 20 monoclonal antibody?
TPO-RAs combining anti-CD 20 monoclonal antibody is developed and marketed by Institute of Hematology & Blood Diseases Hospital, China (see full Institute of Hematology & Blood Diseases Hospital, China pipeline at /company/institute-of-hematology-blood-diseases-hospital-china).
Is TPO-RAs combining anti-CD 20 monoclonal antibody also known as anything else?
TPO-RAs combining anti-CD 20 monoclonal antibody is also known as TPO-R agonist & anti-CD 20 monoclonal antibody.
What development phase is TPO-RAs combining anti-CD 20 monoclonal antibody in?
TPO-RAs combining anti-CD 20 monoclonal antibody is FDA-approved (marketed).
Related
- Manufacturer: Institute of Hematology & Blood Diseases Hospital, China — full pipeline
- Also known as: TPO-R agonist & anti-CD 20 monoclonal antibody
- Compare: TPO-RAs combining anti-CD 20 monoclonal antibody vs similar drugs
- Pricing: TPO-RAs combining anti-CD 20 monoclonal antibody cost, discount & access